Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese CRO JCL Bioassay Sales And Profits Increase

This article was originally published in PharmAsia News

Executive Summary

Japanese contract research organization JCL Bioassay announced April 30 results for FY2008. The company achieved a record ¥2.48 billion in sales, a 7 percent increase. The company's business profit increased by 40.6 percent to ¥502 million, regular profit increased by 32.3 percent to ¥437 million, and net profit increased by 11.3 percent to ¥259 million. Bioanalysis service accounts for 80 percent of JCL Bioassay's sales. For the fiscal year 2009, JCL Bioassay estimates sales, business profit and regular profit increases by 3.5, 11.2 and 3.8 percent, respectively. The company cites a continuous outsourcing trend in pharmaceutical companies. (Click here for more - Japanese language

You may also be interested in...



EU Pushes For Compulsory Licensing Of Drugs & Vaccines In Health Crises

The EU has published an action plan that is intended to upgrade the bloc’s intellectual property framework while ensuring that goods such as medicines and vaccines are made as widely available as possible. The initiative is part of wide-ranging plans to support member states’ recovery from the pandemic crisis and help ensure the EU’s resilience to future health threats.

Execs On The Move: New CEO For Humacyte; Internal Moves At Trinity Biotech, CVRx, Oventus Medical And Cancer Genetics

Trinity Biotech's new CFO is an internal move; Humacyte replaces CEO; chief strategy officer role for former CVRx CFO; and more.

Teva Slapped With €60m Fine Over Unlawful EU Provigil Delay

Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel